Class Action Targets VistaGen After 80% Stock Plunge

Vistagen Therapeutics, Inc. -2.33%

Vistagen Therapeutics, Inc.

VTGN

0.59

-2.33%

Levi & Korsinsky, LLP has filed a proposed class action seeking damages for investors who bought VistaGen Therapeutics securities between April 1, 2024 and December 16, 2025. The suit follows a sharp stock drop after the company reported its Phase 3 study failed to meet its primary endpoint, sending shares down more than 80% on December 17, 2025. A lead plaintiff deadline of March 16, 2026 has been set.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602180900PR_NEWS_USPR_____NY80923) on February 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.